America will wake up on new years day in search of a hangover cure. In California, they'll find one in legal recreational marijuana. The state is set make the move in just four days, which will change everything for the hundreds of marijuana companies operating in the state, including more transparency for consumers.
There was a time when the worlds of sports and politics hardly ever mixed, but that all changed in 2017. It's been one of the craziest years for sports on record, with big wins for some and even bigger losses for others. Nick Dimengo, Senior Dditor at FHM Magazine breaks down all the most memorable sports moments from the past year.
While President Trump is celebrating his win on tax reform at Mar-a-Lago, everyone else is wondering what policy he will take on next. Despite his recent success, divisions within the GOP could make it hard for the president to get another major legislative win in the new year.
Conditions have been mostly nice for travelers flying ahead of and on Christmas Day, but some naughty disruptions plagued those flying with Southwest Airlines again this year.
Gift cards make great stocking stuffers — just as long as you don't stuff them in a drawer and forget about them after the holidays.
Big Business This Week is a guided tour through the biggest market stories of the week, from winning stocks to brutal dips to the facts and forecasts generating buzz on Wall Street.
Bristol Myers Squibb agreed to buy schizophrenia drug maker Karuna Therapeutics in a $14 billion deal.
Supermarket chain Ralphs is facing a new lawsuit from the state of California.
Shake Shack is giving out free fried chicken sandwiches, bacon cheese fries and milkshakes nationwide.
The IRS is announcing a voluntary disclosure program.
Lionsgate announced its studio division is going to spin off in a merger with Screaming Eagle Acquisition Corp., which is a special purpose acquisition company.
A new report suggests that it's getting more difficult for an average American to afford a home.
The Food and Drug Administration warned consumers about a copycat version of the diabetes drug Ozempic.
